SCHEMBL221999

SCHEMBL221999

C=C(C)C(=O)OCCOCCOP(=O)([O-])OCC[N+](C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
LMNA P02545 2/20 0.46
AKT1 P31749 2/20 0.46
ESR1 P03372 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
CDC25A P30304 1/20 0.46
AGTR1 P30556 1/20 0.46
ADRA1A P35348 1/20 0.46
KCNH2 Q12809 1/20 0.46
ADRA1D P25100 1/20 0.44
PTAFR P25105 1/20 0.44
HTR1D P28221 1/20 0.44
HTR2C P28335 1/20 0.44
ADRA1B P35368 1/20 0.44
DRD3 P35462 1/20 0.44
TMEM97 Q5BJF2 1/20 0.44
MAPT P10636 1/20 0.41
CHRM5 P08912 1/20 0.40
CHRM1 P11229 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL35785 0.96 SMN1; SMN2 (0.49) THRBSMN1; SMN2LMNAAKT1ESR1
SCHEMBL20401677 0.96 SMN1; SMN2 (0.49) THRBSMN1; SMN2LMNAAKT1ESR1
Phosphocholine SCHEMBL12979922 0.90 SMN1; SMN2 (0.45) THRBSMN1; SMN2LMNAAKT1ESR1
Phosphoric Acid SCHEMBL30511659 0.88 THRB (0.53) THRBSMN1; SMN2LMNAAKT1ESR1
SCHEMBL18139544 0.88 THRB (0.56) THRBADRA1DPTAFRHTR1DHTR2C
Lithium Ion SCHEMBL18140320 0.88 THRB (0.56) THRBADRA1DPTAFRHTR1DHTR2C
Potassium Ion SCHEMBL18139687 0.88 THRB (0.56) THRBADRA1DPTAFRHTR1DHTR2C
SCHEMBL18140774 0.88 THRB (0.56) THRBADRA1DPTAFRHTR1DHTR2C
SCHEMBL18141475 0.88 THRB (0.56) THRBADRA1DPTAFRHTR1DHTR2C
Lithium Ion SCHEMBL18139459 0.88 THRB (0.56) THRBADRA1DPTAFRHTR1DHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3896074-B1 METHOD, KIT, AND DEVICE FOR PREPARING GLYCAN FROM GLYCOPROTEIN AIST (JP) 2023-10-25 EP disclosed
WO-2022235329-A1 BRAIN-TARGETED ANTIBODY NANOPARTICLE FOR NEURODEGENERATIVE DISEASES THERAPY UNIVERSITY OF SOUTH CAROLINA (US) 2022-11-10 WO disclosed
CN-108885190-B Biosensor and biochip TDK株式会社 2022-06-24 CN disclosed
US-20220017648-A1 Method, Kit, and Device for Preparing Glycan from Glycoprotein SUMITOMO BAKELITE CO., LTD. (JP) 2022-01-20 US disclosed
EP-3896074-A1 METHOD, KIT, AND DEVICE FOR PREPARING GLYCAN FROM GLYCOPROTEIN NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2021-10-20 EP disclosed
US-11136344-B2 Purification agent for sugar chain or glycopeptide, and use thereof SUMITOMO BAKELITE CO., LTD. (JP) 2021-10-05 US disclosed
CN-113383003-A Method, kit and apparatus for producing sugar chain from glycoprotein 国立研究开发法人产业技术综合研究所 2021-09-10 CN disclosed
EP-3394622-B1 REAGENT DILUENT BIOMERIEUX SA (FR) 2021-08-04 EP disclosed
EP-3650456-B1 PURIFICATION AGENT FOR SUGAR CHAIN OR GLYCOPEPTIDE, AND USE THEREOF SUMITOMO BAKELITE CO (JP) 2021-07-07 EP disclosed
US-11009505-B2 Reagent diluent BIOMERIEUX (FR) 2021-05-18 US disclosed
US-20090042190-A1 Method of detecting gene SUMITOMO BAKELITE COMPANY LIMITED (JP) 2009-02-12 US disclosed
US-7438860-B2 Droplet discharging head and microarray manufacturing method SEIKO EPSON CORPORATION (JP) 2008-10-21 US disclosed
EP-1930422-A1 METHOD FOR PRODUCING CDNA AND RNA CHAINS AND NUCLEOTIDE-IMMOBILIZED SUPPORT Sumitomo Bakelite Company, Ltd. (JP) 2008-06-11 EP disclosed
EP-1908848-A1 METHOD FOR DETECTION OF GENE Sumitomo Bakelite Company, Ltd. (JP) 2008-04-09 EP disclosed
US-7323224-B2 Liquid dispense method and microarray manufacturing method SEIKO EPSON CORPORATION (JP) 2008-01-29 US disclosed
US-7166476-B2 Allowing an antibody or an antibody complex which reacts specifically to the antigenic substance and binds to the antigenic substance to give a selective agglutination of the insoluble carrier particles KYOWA MEDEX CO., LTD. (JP) 2007-01-23 US disclosed
US-20060177585-A1 Liquid dispense method and microarray manufacturing method KAZUHIKO ISHIHARA (JP) 2006-08-10 US disclosed
US-20050008497-A1 Droplet discharging head and microarray manufacturing method SEIKO EPSON CORPORATION (JP) 2005-01-13 US disclosed
US-20030166302-A1 Highly reproducible agglutination immunoassay method and reagents FUJIREBIO INC. (JP) 2003-09-04 US disclosed
EP-1314982-A1 HIGHLY REPRODUCIBLE AGGLUTINATION IMMUNOASSAY METHOD AND REAGENTS KYOWA MEDEX CO., LTD. (JP) 2003-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11136344-B2 Purification agent for sugar chain or glycopeptide, and use thereof FUT5, MANBA, MGAM THRB 711/4885SMN1; SMN2 3076/4885LMNA 1865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.